Letters to the Editor Archives - Innovations in Clinical Neuroscience

Letters to the Editor: Post-SSRI Sexual Dysfunction: Challenges and Treatment Approaches

Innov Clin Neurosci. 2026;23(1–3):5–9. Dear Editor: Selective serotonin reuptake inhibitors (SSRIs) have long been a cornerstone in the treatment of mood disorders, particularly depression and anxiety. Since their introduction in

Letters to the Editor: Response to “Burnout and Ethical Awareness in Mental Health Professionals: A Correlational Study”

Innov Clin Neurosci. 2026;23(1–3):5–9. Dear Editor: We read with great interest the study by Fatima and Ilyas,1 which explores the relationship between ethical awareness and burnout among mental health professionals

Letters to the Editor: Responding to Correspondence on “Burnout and Ethical Awareness in Mental Health Professionals: A Correlational Study”

Innov Clin Neurosci. 2026;23(1–3):5–9. Dear Editor: We thank Sah and Kumbhalwar for their careful reading of our article, “Burnout and Ethical Awareness in Mental Health Professionals: A Correlational Study,”1 and

Letters to the Editor: “AI Literacy” is a Deflection of Responsibility

Innov Clin Neurosci. 2026;23(1–3):5–9. Dear Editor: Pierre et al1 carefully document a case of a phenomenon that has received widespread media attention in recent months. The authors correctly note that

Letters to the Editor: Response to “‘AI Literacy’ is a Deflection of Responsibility”

Dear Editor: I thank Dr. Jutla for his comments on our case report1 of artificial intelligence (AI)–associated psychosis. As we predicted, other cases have followed in the academic literature, along

Letter to the Editor: A Report of Early-onset Psychosis Occurring in the Context of a Perinatal Stroke History

Dear Editor: Although poststroke psychosis is a reasonably well-established clinical phenomenon,1 few articles describing the development of psychotic symptoms on the background of a perinatal stroke history or other anoxic

Letter to the Editor: A First Seizure After 2,000mg Fluoxetine May or May Not Be Due to Intoxication

Dear Editor: I read with interest the article by Allen et al1 about a 19-year-old male transgender patient who developed seizures after intentionally taking 2,000mg of fluoxetine. His medical history

Letter to the Editor: Response to “A First Seizure After 2,000mg Fluoxetine May or May Not be Due to Intoxication”

Dear Editor: We thank the author for their thoughtful and insightful comments on our case report.1 We fully agree that fluoxetine has a known potential to trigger seizures, especially in

Letter to the Editor: Before Attributing Compulsive Chewing to Amphetamines, Alternative Causes Must Be Thoroughly Ruled Out

Innov Clin Neurosci. 2025;22(4–6):11–13. Dear Editor: We read with interest the article by Free et al1 about a 32-year-old female patient with a history of migraine, gastroesophageal reflux disease (GERD)

Letter to the Editor: Response to “Before Attributing Compulsive Chewing to Amphetamines, Alternative Causes Must Be Thoroughly Ruled Out”

Innov Clin Neurosci. 2025;22(4–6):11–13. Dear Editor: We greatly appreciate the letter to the editor regarding the article “Compulsive Biting and Chewing with Mixed Amphetamine Salts: A Case Report” by Free

Letter to the Editor: Challenges of Psychiatric Diagnostic Support Using Functional Near-infrared Spectroscopy

Innov Clin Neurosci. 2025;22(4–6):11–13. Dear Editor: Approximately 15 years have passed since functional near-infrared spectroscopy (fNIRS) was approved for use as an auxiliary diagnostic tool for the differential diagnosis of

Letter to the Editor: More Evidence is Needed Before Recommending Magic Mushrooms for the Treatment of Complicated Migraines

Innov Clin Neurosci. 2025;22(1–3):11–13. Dear Editor: I read with interest Lawrence’s article about a 33-year-old male patient with migraine with aura who self-experimented with psilocybin for his migraine attacks, which

Letter to the Editor: Response to “More Evidence is Needed Before Recommending Magic Mushrooms for the Treatment of Complicated Migraines”

Innov Clin Neurosci. 2025;22(1–3):11–13. Dear Editor: Thank you for your interest in this case report1 and for your insightful comments. I appreciate the thoroughness of your feedback and concur with

Letter to the Editor: Sex Differences in Brain Networks Might Explain Why Female Patients with Schizophrenia Experience More Side Effects from Antipsychotic Medications

Innov Clin Neurosci. 2025;22(1–3):11–13. Dear Editor: Emerging data on sex differences in the efficacy and tolerability of antipsychotics in patients with schizophrenia are not taken into account in current guidelines,

Letter to the Editor: Schizophrenia with catatonia and stupor is an emergency and requires immediate psychiatric and neurological evaluation

Innov Clin Neurosci. 2024;21(10–12):8. Dear Editor: The interesting article by Zuckerberg et al1 on a 29-year-old male patient with schizophrenia, catatonia, and stupor associated with an enlarged cavum septum pellucidum

Letter to the Editor: Activation of the Serotonergic Neurotransmission is a Double-edged Sword in the Treatment of Burning Mouth Syndrome

Innov Clin Neurosci. 2024;21(7–9):8–9. Dear Editor: In the treatment of chronic pain of unknown cause, contradictions can arise; a drug for the treatment of a disease might be a cause

Letter to the Editor: Responding to commentary: addressing points raised in the correspondence about “ChatGPT and Transcranial Direct Current Stimulation for Chronic Pain”

Innov Clin Neurosci. 2024;21(4–6):8–10. Funding/financial disclosures. The authors have no conflicts of interest relevant to the contents of this letter. No funding was received for the preparation of this letter.

Letter to the Editor: Response to “ChatGPT and Transcranial Direct Current Stimulation for Chronic Pain”

Letter to the Editor: Responding to correspondence on “Clinical Outcome Assessment Instruments in Schizophrenia: A Scoping Literature Review with a Focus on the Potential of Patient-reported Outcomes”

Innov Clin Neurosci. 2024;21(4–6):8–10. Funding/financial disclosures. Dr. Citrome is a consultant for AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris

Letter to the Editor: Response to “Clinical Outcome Assessment Instruments in Schizophrenia: A Scoping Literature Review with a Focus on the Potential of Patient-reported Outcomes”

Innov Clin Neurosci. 2024;21(4–6):8–10. Funding/financial disclosures. Dr. Zaragoza Domingo is co-author and intellectual property owner of the EPICOG-SCH battery. No funding was received for the preparation of this letter. Dear

DIGITAL EDITION

ARCHIVES

Category: Letters to the Editor